ERBB2 and breast cancer: Singh et al. [18] demonstrated that five unique HER2/neu fragments secreted as a fusion protein with a truncated, nonhemolytic form of LLO and expressed in recombinant Lm controlled the growth of established NT2 mammary tumors, with the antitumor effect driven by a population of anti-HER2/neu CD8+ cytotoxic T cells [18].